Survival of subjects receiving epoprostenol following a diagnosis of PAH within a period of 6 months or less.
| Time in Study, yrs | No. of Subjects* | No. of Deaths | No. of Subjects Withdrawn for Other Reasons | Survival Rate (at start of year) |
|---|---|---|---|---|
| 1 | 37 | 12 | 2 | 1.00 |
| 2 | 23 | 6 | 1 | 0.66 |
| 3 | 16 | 1 | 12 | 0.49 |
| 4 | 3 | 0 | 3 | 0.45 |
↵* At the start of the study year (time in study).